Gossamer Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Gossamer Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.1 times its market value (net debt). Lower than 95% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-182.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 91% of Healthcare companies in United States.
Cash Cushion Ratio
1.1× debtDebt, after subtracting cash, is 1.1 times its market value (net debt).
Lower than 95% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Gossamer Bio, Inc. made a loss over the last year. Gossamer Bio, Inc. owes $2.22 for every $1 it owns. Gossamer Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGossamer Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.62Gossamer Bio, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$58 MThe total market value of all of Gossamer Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeGossamer Bio, Inc.'s net worth is negative ($94 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
2.22×Gossamer Bio, Inc. owes $2.22 for every $1 it owns, so it owes more than it owns, higher than 97% of Healthcare companies in United States.
Dividend yield
NoneGossamer Bio, Inc. does not currently pay a dividend.
Revenue growth
-58%Revenue fell 58% in the year to Dec 2025.
Profit growth
LossGossamer Bio, Inc. made a loss in each of the last two years.
Profit margin
-351.5%Gossamer Bio, Inc. lost $351 for every $100 of revenue.
Interest cover
Not coveredGossamer Bio, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtGossamer Bio, Inc. had $66 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Gossamer Bio, Inc. owe compared with what it owns?
Gossamer Bio, Inc. owes $2.22 for every $1 it owns, so it owes more than it owns, higher than 97% of Healthcare companies in United States.
Does Gossamer Bio, Inc. pay a dividend?
No. Gossamer Bio, Inc. does not currently pay a dividend.
Is Gossamer Bio, Inc.'s revenue growing?
Revenue fell 58% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.